Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
An amylin analog. Native amylin is co-secreted with insulin and changes meal size and gastric emptying. This sheet has no amylin marker, so the scored lines are emptying, appetite, and nausea.
CagriSema is a pharmaceutical combination idea. It is not a research-vial instruction, and cagrilintide is not semaglutide.
Amylin receptor signaling is the class story: smaller meals and slower gastric emptying. Nausea is the adverse theme the protocol library names for amylin analogs, and it gets louder next to a GLP-1 agonist.
This sheet cannot score the amylin receptor itself. The stored arrows are the downstream themes only. A pharmaceutical combination program is not a vial dose.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
CagriSema copy · unverified
Public discussions copy pharmaceutical cagrilintide plus semaglutide programs onto research vials. The protocol library grades those copies as F. The GI burden of stacking the two is the part that belongs on this sheet.
From the Catalyst protocol research library. Community schedules there are Grade F and are not a dose.